MLN4924 and Neddylation Pathway Inhibition: Mechanistic Insights for Solid Tumor Research

Introduction

The neddylation pathway represents a pivotal regulatory axis in eukaryotic cell biology, orchestrating proteostasis, cell cycle progression, and signal transduction through the post-translational conjugation of NEDD8 to substrate proteins. Central to this process is the NEDD8-activating enzyme (NAE), whose inhibition has emerged as a promising strategy in cancer research. MLN4924 (Pevonedistat) is a first-in-class, potent, and selective NAE inhibitor that has rapidly become an essential chemical probe in elucidating the biological and therapeutic implications of neddylation pathway inhibition, particularly in solid tumor models. Recent research continues to expand our understanding of the molecular consequences of NAE inhibition, including its intersection with mTORC1 signaling and non-cullin neddylation substrates, as exemplified by the work of Zhang et al. (The EMBO Journal, 2025).

The Molecular Mechanism and Selectivity of MLN4924

MLN4924 (B1036) operates by competitively binding the ATP-binding site of NAE, with an IC₅₀ value of 4 nM, thus preventing the activation of NEDD8 and the subsequent neddylation cascade. This blockade reduces the formation of Ubc12–NEDD8 thioester intermediates and the conjugation of NEDD8 to cullin proteins, resulting in the suppression of cullin-RING ligase (CRL) activity. CRLs are the largest family of E3 ubiquitin ligases and are responsible for the ubiquitination and proteasomal degradation of a multitude of regulatory substrates, including those involved in cell cycle regulation, DNA replication, and stress responses.

Importantly, MLN4924 demonstrates high selectivity for NAE over related E1 family members such as UAE, SAE, UBA6, and ATG7, with IC₅₀ values orders of magnitude higher for these enzymes. This selectivity underpins its broad utility as a tool compound for studying neddylation-specific mechanisms in cancer biology research and anti-cancer therapeutic development.

MLN4924 in Solid Tumor Models: Functional Outcomes and Cellular Pathways

In vitro, MLN4924 induces dose-dependent inhibition of NAE activity, as demonstrated in HCT-116 colorectal carcinoma cells, and leads to the accumulation of CRL substrates such as CDT1, which precipitates cell cycle arrest and apoptotic cell death. The downstream effects of neddylation pathway inhibition include impaired DNA replication origin licensing, stabilization of cell cycle inhibitors, and increased genomic instability.

In vivo, MLN4924 exhibits robust anti-tumor activity in xenograft models of solid tumors, including HCT-116, H522 lung carcinoma, and Calu-6 lung carcinoma. Subcutaneous administration at 30 mg/kg and 60 mg/kg results in significant tumor growth inhibition with minimal systemic toxicity, as evidenced by good tolerability and negligible weight loss. These findings support its continued evaluation in preclinical and clinical studies targeting the ubiquitin-proteasome system in cancer.

Expanding the Scope: Neddylation Beyond Cullins and Integration with mTORC1 Signaling

While the canonical function of neddylation was long thought to be confined to cullin family proteins, accumulating evidence highlights a broader substrate landscape. The recent study by Zhang et al. (The EMBO Journal, 2025) demonstrates that RHEB, a small GTPase and critical upstream activator of mTORC1, is directly neddylated by the UBE2F-SAG axis. Neddylation of RHEB at lysine 169 enhances its lysosomal localization and GTP-binding affinity, promoting sustained mTORC1 activity—a key driver of cell growth and tumorigenesis, particularly in hepatocellular carcinoma (HCC).

Genetic ablation of UBE2F in mouse liver impairs RHEB neddylation, leading to reduced mTORC1 signaling, inhibition of cell cycle progression, and the induction of autophagy. Notably, liver-specific knockout of Ube2f protects against steatosis and tumorigenesis induced by PTEN loss, underscoring the pathophysiological relevance of neddylation in oncogenic transformation. Furthermore, clinical data reveal that UBE2F expression correlates with mTORC1 activity and overall survival in HCC patients, suggesting prognostic as well as therapeutic implications.

These findings extend the functional consequences of neddylation pathway inhibition with MLN4924 beyond cullin-CRL regulation, highlighting the potential to modulate non-cullin targets such as RHEB and, consequently, key oncogenic signaling nodes like mTORC1. Such mechanistic insights provide a compelling rationale for targeting neddylation in the context of solid tumors with dysregulated mTORC1 signaling.

Practical Considerations for MLN4924 Use in Experimental Systems

For laboratory applications, MLN4924 is supplied as a solid (molecular weight 443.53 Da), with excellent solubility in DMSO (≥22.18 mg/mL) and ethanol (≥42.2 mg/mL), but is insoluble in water. Solutions should be prepared fresh and stored at −20°C for short-term use to maintain stability. Optimization of dosing regimens and vehicle controls is critical for accurate assessment of neddylation pathway inhibition in cell-based and in vivo models.

When designing experiments to dissect the role of neddylation in cell cycle regulation, CRL ubiquitination inhibition, or tumor growth inhibition in xenograft models, investigators should consider combining genetic and pharmacological approaches to distinguish on-target effects from potential off-target consequences. For example, parallel use of siRNA or CRISPR-mediated NAE knockdown can provide orthogonal validation of MLN4924-induced phenotypes.

Emerging Directions: Therapeutic Targeting and Biomarker Discovery

The intersection of neddylation and oncogenic signaling, as illuminated by the non-cullin substrate RHEB, suggests new opportunities for biomarker development and patient stratification in anti-cancer therapeutic development. Monitoring neddylation status of RHEB or expression levels of NEDD8 pathway components (e.g., UBE2F, SAG) may inform response to selective NAE inhibitors in clinical settings, particularly in solid tumors characterized by heightened mTORC1 activity or PTEN loss.

Moreover, MLN4924's ability to modulate both proteostasis and key signaling pathways positions it as a versatile tool for dissecting complex tumor biology. Future research may leverage MLN4924 to explore combinatorial therapeutic strategies, such as pairing with mTOR inhibitors or immune checkpoint blockade, to overcome resistance mechanisms and enhance anti-tumor efficacy.

Contrasting Perspectives and Novel Contributions

While previous reviews, such as "MLN4924: Targeting Neddylation Pathways for Solid Tumor Research", have comprehensively summarized the pharmacological and preclinical aspects of MLN4924, this article distinguishes itself by integrating recent mechanistic insights from the study of RHEB neddylation and mTORC1 regulation (Zhang et al., 2025). Specifically, we emphasize the expanding substrate repertoire of the neddylation pathway and its translational significance for solid tumor models, moving beyond cullin-centric frameworks. This approach not only updates the field with the latest evidence but also offers practical guidance for leveraging MLN4924 to interrogate non-cullin neddylation targets and oncogenic signaling circuits, providing a nuanced perspective for cancer biology research and therapeutic innovation.

Conclusion

MLN4924 remains a cornerstone compound for investigating the biological and therapeutic dimensions of neddylation pathway inhibition. Its impact on CRL-mediated ubiquitination, cell cycle regulation, and, as recent evidence suggests, mTORC1 signaling via non-cullin substrates like RHEB, underscores its value in cancer research. As the field moves toward more sophisticated models and combinatorial strategies, MLN4924 is poised to facilitate both fundamental discoveries and translational advances in solid tumor oncology.